Goldman Sachs’s Ambrx Biopharma Inc AMAM Stock Holding History

Goldman Sachs’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-399,648	Closed	-$5.69M	–	5993
2023 Q4	$5.69M	Buy	+399,648	New	+$4.54M	﹤0.01%	3044

Goldman Sachs's AMAM Position: Q1 2024 in Review

Goldman Sachs sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 399,648 shares — an estimated $5.69M sold.

Goldman Sachs first reported a position in AMAM in Q4 2023 and held it in 1 quarter. The position peaked at $5.69M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Goldman Sachs reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Goldman Sachs sold 399,648 Ambrx Biopharma Inc shares in Q1 2024, an estimated $5.69M.
Goldman Sachs first reported a position in Ambrx Biopharma Inc in Q4 2023 and held it in 1 quarter.
Goldman Sachs's Ambrx Biopharma Inc position peaked at $5.69M in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.